Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQ: IRWD · Real-Time Price · USD
3.110
+0.220 (7.61%)
At close: Nov 12, 2025, 4:00 PM EST
3.120
+0.010 (0.32%)
After-hours: Nov 12, 2025, 4:17 PM EST
Ironwood Pharmaceuticals Revenue
Ironwood Pharmaceuticals had revenue of $122.06M in the quarter ending September 30, 2025, with 33.26% growth. This brings the company's revenue in the last twelve months to $338.99M, down -10.42% year-over-year. In the year 2024, Ironwood Pharmaceuticals had annual revenue of $351.41M, down -20.63%.
Revenue (ttm)
$338.99M
Revenue Growth
-10.42%
P/S Ratio
1.37
Revenue / Employee
$1,339,870
Employees
253
Market Cap
505.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 351.41M | -91.33M | -20.63% |
| Dec 31, 2023 | 442.74M | 32.14M | 7.83% |
| Dec 31, 2022 | 410.60M | -3.16M | -0.76% |
| Dec 31, 2021 | 413.75M | 24.23M | 6.22% |
| Dec 31, 2020 | 389.52M | -38.89M | -9.08% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IRWD News
- 2 days ago - Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance - Business Wire
- 19 days ago - Ironwood Stair & Rail Inc. Recognised With 2025 Consumer Choice Award for Stairs and Railings in Southern Alberta - Accesswire
- 3 months ago - Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance - Business Wire
- 6 months ago - Ironwood Pharmaceuticals Reports First Quarter 2025 Results - Business Wire
- 7 months ago - Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference - Business Wire
- 7 months ago - Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance - Business Wire
- 7 months ago - Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support - Business Wire
- 7 months ago - Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug - Benzinga